To address this issue, the anti-IgLON5 disease composite score (ICS), covering the main clinical manifestations of the disease grouped into five domains (bulbar, sleep, movement disorders, cognition, and other symptoms), has recently been developed and tested in previously published nationwide cohorts from Spain (Barcelona cohort) and Germany (GENERATE cohort) [12]. Here, IGLON5 is linked to movement disorder.